If you have been reading about PT-141 code and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-09-29. Where a claim depends on a specific study, the study is described rather than over-claimed.
Early work on melanocortin analogs in the 1980s and 1990s produced peptides intended to influence pigmentation and appetite. One of these, melanotan II, was observed to affect sexual desire as an incidental finding in self-administration reports. Researchers then pursued analogs with altered receptor selectivity and improved handling characteristics, and PT-141 emerged from that program in the late 1990s. The development path moved from dermatology and metabolism toward a central nervous system application, a shift that shaped both trial designs and the eventual label.
Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.
Bremelanotide is a synthetic cyclic heptapeptide developed under the research code PT-141. The code reflects its position in an internal compound series rather than a chemical classification, and the name bremelanotide was later adopted for regulatory filings. Structurally it belongs to the melanocortin peptide family and shares a core sequence motif with alpha-melanocyte-stimulating hormone. The compound is supplied as an acetate salt in aqueous solution for injection. In reference literature it is indexed under both the code and the generic name, a dual listing that can complicate database searches.
Bremelanotide, developed under the code PT-141, is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone. Its structure is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, with a lactam bridge joining the aspartate and lysine side chains. The molecule has the formula C50H68N14O10 and a monoisotopic mass near 1025 daltons. It is commonly prepared as the acetate salt and appears as a white to off-white lyophilised powder in solid form. The free acid is the pharmacologically relevant species, while the counter-ion improves handling and dissolution.
Early research on PT-141 grew out of work on melanotan II, a related cyclic peptide studied for pigmentation. Investigators observed that centrally acting melanocortin agonists also influenced sexual behaviour in animal models, and the programme shifted toward that endpoint. A nasal formulation was evaluated in clinical trials but showed inconsistent absorption, and later studies used subcutaneous administration instead. Regulatory approval in the United States followed in 2019 for a defined population of premenopausal women with acquired, generalised hypoactive sexual desire disorder. That approval was specific to that group rather than a broad indication.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H68N14O10 | Cyclic heptapeptide core |
| Molecular weight | 1025.2 g/mol | Calculated for the free base |
| CAS registry number | 189691-06-3 | Free base; the acetate salt has a separate entry |
| Solubility class | Water-soluble | Freely soluble in aqueous media near neutral pH |
| Typical storage | 2 to 8 °C | Protect from light; avoid repeated freeze-thaw cycles |
After subcutaneous dosing, peak plasma concentrations appear within roughly one hour, and elimination is fast, with a half-life on the order of a few hours. Degradation is mainly proteolytic, and at least one circulating fragment retains receptor activity, so parent-drug levels alone do not describe total exposure. Clearance does not depend heavily on hepatic cytochrome enzymes, which lowers the likelihood of common metabolic interaction routes. Data in renal or hepatic impairment are limited. Repeated dosing does not appear to produce marked accumulation given the short half-life.
Reported pharmacodynamic effects include transient rises in blood pressure and heart rate, flushing, nausea and headache, appearing soon after dosing and resolving within hours. These responses were dose-related in early studies and shaped the label's cardiovascular cautions and blood pressure monitoring advice. Gastrointestinal upset is the most frequent reason cited for discontinuation in trials. Whether the vascular signal attenuates with repeated use is not settled. Central effects on desire are described as emerging over weeks rather than immediately, which points to a cumulative rather than acute process.
The compound binds several melanocortin receptor subtypes rather than a single target, with the strongest functional activity reported at MC4R and measurable activity at MC1R, MC3R and MC5R. MC4R populations are dense in hypothalamic nuclei that integrate energy balance, autonomic tone and reproductive behaviour, which is the anatomical basis for the proposed pro-desire effect. Because binding is not subtype-selective, pigmentary and vascular effects accompany central activity. Improving subtype selectivity is an active area of analogue design. Direct causal mapping from receptor occupancy to reported desire change in humans is not fully established.
Evidence outside the studied population is sparse. Trials have concentrated on premenopausal women with a defined diagnosis, and data for postmenopausal women, men, and people taking interacting medications remain limited. Non-prescription use of the peptide for comparable goals is widespread but is not supported by published controlled data. Observed changes in blood pressure have drawn attention to cardiovascular monitoring during use. The literature generally frames the compound as a targeted receptor agonist rather than a general libido enhancer, and basic questions about mechanism and long-term safety are unresolved.
Bremelanotide functions as an agonist at several melanocortin receptor subtypes, with the strongest functional activity reported at the MC4 subtype. MC4 receptors sit in hypothalamic circuits that influence appetite, energy balance, and components of sexual behaviour. Rodents lacking functional MC4 receptors show altered mating behaviour, which supports a role for this pathway in desire. The precise sequence of events connecting receptor activation to reported human effects remains only partly characterised. Because the same receptor family governs pigmentation and inflammatory signalling, selectivity is a recurring theme in pharmacological discussion.
Clinical programmes in this area have relied mainly on randomised, double-blind, placebo-controlled designs in premenopausal women. Primary endpoints usually combine a validated questionnaire covering desire domains with counts of satisfying sexual events and a separate measure of distress. Reported outcomes show statistically significant but modest average improvement over placebo, with wide individual variation. Adverse events such as nausea, flushing, and headache occur frequently and can limit tolerability. Whether short-term trial gains translate into lasting change for most users is an open question.
Across literature and commercial listings, the substance appears under several names, including bremelanotide, PT-141, and various brand designations. A CAS registry number provides a unique identifier for the compound, aiding retrieval from chemical databases. Synonym lists may also contain early development codes and descriptive chemical names. When consulting sources, researchers need to confirm that the cited names refer to the same molecular structure to avoid confusion. Naming consistency matters especially when comparing analytical data across publications.
PT-141 is a synthetic cyclic heptapeptide whose development code is bremelanotide. It belongs to the class of melanocortin receptor agonists and acts by mimicking endogenous peptide hormones. The compound originated from research on melanotan II, where investigators exploring derivatives found distinct pharmacological features. Unlike the parent compound, PT-141 showed effects on pathways related to sexual desire and function in early studies, prompting its development as a separate candidate. Its molecular design aimed to separate receptor activity from pigmentary effects.
The compound emerged from a research programme examining melanocortin analogues for effects on skin pigmentation. During early human studies, participants reported spontaneous erections as an unexpected side effect, which redirected development toward sexual function rather than tanning. An intranasal formulation was investigated in clinical trials but did not reach market approval. A subcutaneous injectable version later completed the regulatory process, and the nasal route does not appear in approved labelling.
Approved use is narrow and jurisdiction-specific. In the United States, the injectable product is authorised for premenopausal women with acquired, generalised hypoactive sexual desire disorder, a diagnosis that requires documented distress. It is not approved for men, for postmenopausal women, or for use alongside hormonal contraceptives under the approved labelling. Outside regulated markets, the same peptide is frequently sold as a research chemical, where identity, purity, and sterility are not independently verified.
Bremelanotide is a synthetic cyclic heptapeptide developed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and appetite signalling. Its structure contains seven amino acid residues joined by a lactam bridge that closes the ring between two side chains. The molecular formula is C50H68N14O10 and the nominal molecular mass is near 1025 daltons. Much of the early laboratory literature refers to the same molecule by the development code PT-141.
In October 2016, the Monetary Authority of Singapore admonished and fined UBS and DBS and withdrew the banking licence from Falcon Private Bank for their alleged role in the Malaysian Sovereign Fund scandal. In 2016, Singapore was rated the world's most expensive city for the third consecutive year by the Economist Intelligence Unit, and this remained true in 2018. The government provides numerous assistance programmes to the homeless and needy through the Ministry of Social and Family Development, so acute poverty is rare. Some of the programmes include providing financial assistance to needy households, providing free medical care at government hospitals, and paying for children's tuition. Other benefits include compensation for gym fees to encourage citizens to exercise, up to S$166,000 as a baby bonus for each citizen, heavily subsidised healthcare, financial aid for the disabled, the provision of reduced-cost laptops for poor students, rebates for costs such as public transport and utility bills, and more. In the 2025 report, Singapore was ranked 13th in the world in the Human Development Index (HDI) with a value of 0.946, making it one of four regions in Asia to be ranked within the top 20, with the other three being Hong Kong, United Arab Emirates, and South Korea.
== History == In 2008 bitcoin was introduced as the first cryptocurrency following the principle outlined by Satoshi Nakamoto in the paper “Bitcoin: A Peer-to-Peer Electronic Cash System.” The project was described as an electronic payment system using cryptographic proof instead of trust. It also mentioned using cryptographic proof to verify and record transactions on a blockchain. The first wallet program, simply named Bitcoin, and sometimes referred to as the Satoshi client, was released in January 2009 by Satoshi Nakamoto as open-source software. In version 0.5 the client moved from the wxWidgets user interface toolkit to Qt, and the whole bundle was referred to as Bitcoin-Qt. After the release of version 0.9, the software bundle was renamed Bitcoin Core to distinguish itself from the underlying network. Bitcoin Core is, perhaps, the best known implementation or client. Forks of Bitcoin Core exist, such as Bitcoin XT, Bitcoin Unlimited, and Parity Bitcoin.
Corey Taylor − vocals, guitar on track 17, additional guitar on tracks 4, 8 and 12 James Root − guitar (on all tracks except 18), drums on track 15 Josh Rand − guitar (on all tracks except 18) Shawn Economaki − bass (on all tracks except 17 and 18) Roy Mayorga − drums (on all tracks except 1, 15, 17 and 18) Additional personnel
Sources: en.wikipedia.org
Stanley Whittingham conceived intercalation electrodes in the 1970s and created the first rechargeable lithium-ion battery, based on a titanium disulfide cathode and a lithium-aluminium anode, although it suffered from safety problems and was never commercialized. John Goodenough expanded on this work in 1980 by using lithium cobalt oxide as a cathode. The first prototype of the modern Li-ion battery, which uses a carbonaceous anode rather than lithium metal, was developed by Akira Yoshino in 1985 and commercialized by a Sony and Asahi Kasei team led by Yoshio Nishi in 1991. Whittingham, Goodenough, and Yoshino were awarded the 2019 Nobel Prize in Chemistry for their contributions to the development of lithium-ion batteries. Lithium-ion batteries can be a fire or explosion hazard as they contain flammable electrolytes. Progress has been made in the development and manufacturing of safer lithium-ion batteries. Lithium-ion solid-state batteries are being developed to eliminate the flammable electrolyte. Lithium and other minerals can have significant issues in mining, with lithium being water intensive in often arid regions and other minerals used in some Li-ion chemistries potentially being conflict minerals such as cobalt. Environmental issues have encouraged some researchers to improve mineral efficiency and find alternatives such as lithium iron phosphate lithium-ion chemistries or non-lithium-based battery chemistries such as sodium-ion and iron-air batteries. Lithium-ion cells can be manufactured to optimize energy density or power density.
At the end of its 2013 fiscal year, Burger King was the second largest chain of hamburger fast food restaurants in terms of global locations, behind industry bellwether McDonald's, which had 32,400 locations. At the end of 2014, Burger King ranked fourth among US food chains in terms of US sales, behind McDonald's, Starbucks, and Subway. Burger King now has over 12,000 stores worldwide. In January 2024, Restaurant Brands International, the owner of the brand, announced it would purchase the largest franchisee of the chain, Carrols Restaurant Group, for around $1 billion. At the time of the announcement, Carrols had 1,022 Burger King locations (along with 60 Popeyes locations). The goal was to remodel 600 of the restaurants, then sell them back to franchisees over five to seven years. The move represented a departure from the existing model of largely franchising locations.
Fibromyalgia can be viewed as a condition defined by nociplastic pain. Nociplastic pain is caused by altered function of pain-related sensory pathways in the periphery and the central nervous system, resulting in hypersensitivity. As of 2023, the underlying processes of nociplastic pain remain poorly understood. Nociplastic pain may be caused by either (1) increased processing of pain stimuli or (2) decreased suppression of pain stimuli at several levels in the nervous system, or both. Nociplastic pain has been referred to as "Nociplastic pain syndrome" because it is coupled with other symptoms including fatigue, sleep disturbance, cognitive disturbance, hypersensitivity to environmental stimuli, anxiety, and depression. Nociplastic pain states can be triggered by a variety of stressors such as trauma, infections, and chronic stressors. A 2024 review reported that symptoms such as fatigue, sleep, memory, and mood problems, and sensitivity to non-painful sensory stimuli were also CNS-driven symptoms that were inherent to nociplastic pain. In 2023, the "Fibromyalgia: Imbalance of Threat and Soothing Systems" (FITSS) model was suggested as a working hypothesis. According to the FITSS model, the salience network (also known as the midcingulo-insular network) may remain continuously hyperactive due to an imbalance in emotional self-regulation, which is reflected by an overactive "threat" system and an underactive "soothing" system. This hyperactivation, along with other mechanisms, may contribute to fibromyalgia.
In very general terms, the viscous stresses in a fluid are defined as those resulting from the relative velocity of different fluid particles. As such, the viscous stresses must depend on spatial gradients of the flow velocity. If the velocity gradients are small, then to a first approximation the viscous stresses depend only on the first derivatives of the velocity. (For Newtonian fluids, this is also a linear dependence.) In Cartesian coordinates, the general relationship can then be written as
Sources: en.wikipedia.org
is the speed of light in a vacuum. The law can be formulated mathematically in the fields of fluid mechanics and continuum mechanics, where the conservation of mass is usually expressed using the continuity equation, given in differential form as
In 1649, German scientist and inventor Otto von Guericke invented the spool vacuum air pump. Guericke's vacuum pump decreased any potential leaks between the piston and the cylinder by utilizing washers made from leather. In Britain, the first effective vacuum pump for scientific purposes was constructed in 1658 by English polymath Robert Hooke, on behalf of Anglo-Irish natural philosopher Robert Boyle. Boyle used the term "air pump" (among others) for his own vacuum pump as well as Guericke's, and they have often been referred to as such ever since. In 1705, English scientist Francis Hauksbee, developed a style of a double-barrelled air pump. Hauksbee's double-barrelled air pump was used primarily for scientific research, and had the ability to create a vacuum.
== History == Kombucha may have originated in the Bohai Sea region of China, but its history is not well documented. At least before the 20th century, some traditional Chinese medicine practitioners used it as a remedy for lung and stomach ailments, but the drink was not widely known across the country. It spread to Russia before reaching Eastern/Central Europe, where it appeared in an 1852 work.It gained popularity in the United States during the turn of the 21st century. In the intervening years, its popularity in the West eclipsed its popularity in China, where it remains less known, though consumption is increasing in many East Asian countries. Numerous myths surrounding the history of kombucha have been perpetrated by Western marketing gimmicks. There is no evidence that kombucha originated in Qin dynasty China and that it was served to Emperor Qin Shi Huang. Furthermore, there is no evidence that kombucha was ever present in Korea or Japan before the late 20th century, making claims that a Korean doctor named Kombu served the drink to Japanese Emperor Ingyo entirely apocryphal. Kombucha was first introduced to Japan from Russia and became a health fad in the country following the publication of Sumako Nakamitsu's 1974 bestseller Kōcha Kinoko Health Methods. Although kombucha (as hǎibǎo) had already been consumed in China before the 1940s, a national craze did not occur until the 1980s as a result of the 1970s craze in Japan.
Glycine max subsp. formosana (Hosok.) Tateishi & H.Ohashi Glycine max nothosubsp. gracilis (Skvortsov) H.Ohashi = G. max subsp. max × G. max subsp. soja Glycine max subsp. max Glycine max subsp. soja (Siebold & Zucc.) H.Ohashi
=== Health === In 1934, at the age of 24, Dorothy began experiencing pain in her hands causing them to become swollen and distorted. She was diagnosed with rheumatoid arthritis, and went to a clinic in Buxton for thermal baths and gold treatments. After some treatment, Hodgkin returned to the lab, where she struggled to use the main switch on the x-ray equipment due to the condition of her hands. She had to create a lever on her own in order to operate the switch. Her condition would become progressively worse and debilitating over time, with deformities in both her hands and feet, and prolonged periods of pain. While Hodgkin spent a great deal of time in a wheelchair in her later years, she remained scientifically active in her career.
Sources: en.wikipedia.org
PT-141 was the internal development code assigned to bremelanotide during preclinical research. Reference sources sometimes index the peptide under the code rather than the generic name. The two terms describe the same molecule.
They are related but distinct cyclic peptides. Melanotan II is an earlier and less selective melanocortin analog. Bremelanotide was developed later with a narrower receptor profile and a defined clinical application.
The reviewed product is given by subcutaneous injection using a single-use autoinjector. Administration occurs under prescription supervision. The device delivers one fixed amount per use rather than a measured or adjustable quantity.
PT-141 was the development code used for bremelanotide during its preclinical and early clinical programme. The peptide is now generally referred to by its international nonproprietary name.